Last reviewed · How we verify

NCT03979729

Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography

Completed Last updated 5 October 2022
What this trial tests

trial testing Routine Screening Mammogram (3D + 2D) in Breast Cancer Screening in 75 participants. Completed in 3 June 2021.

Timeline
22 September 2016
Primary endpoint
7 May 2020
3 June 2021

Quick facts

Lead sponsorNew Mexico Cancer Research Alliance
StatusCompleted
Study typeOBSERVATIONAL
Enrollment75
Start date22 September 2016
Primary completion7 May 2020
Estimated completion3 June 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

New Mexico Cancer Research Alliance — full company profile →

Who can join

40 and older, female only, with Breast Cancer Screening. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Three-dimensional (3D) + two-dimensional (2D)- mammography may have particular value for minority, rural, and underserved women in New Mexico by decreasing recall rates and improving diagnostic sensitivity, thus alleviating some of the unique burdens associated with breast cancer screening in the multi-ethnic and underserved New Mexico patient population. Primary objective: To compare recall rates using 3D + 2D- vs. 2D- mammogram in New Mexico women undergoing screening mammogram between 2013 and 2016. Secondary objectives: Evaluate knowledge, attitudes, perceived barriers, intentions, decisional influences, and other psychosocial/cultural factors influencing breast cancer screening among medically underserved patients and assess what impact 3D + 2D-mammography might have on those perceptions; Determine primary care providers' knowledge, attitudes, beliefs, and preferences regarding 3D + 2D- vs. 2D- mammography; evaluate breast cancer detection rate and biopsy positive predictive value for screening mammograms using 3D + 2D- vs. 2D using PENRAD data; evaluate screening outcome, compliance with recall recommendations, breast cancer detection rate, positive predictive value, and demographics of interest in New Mexico women undergoing screening and offered 3-D mammography (retrospective chart review).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Breast Cancer Screening Among Medically Underserved Women in New Mexico: Potential for Lower Recall Rates with Digital Breast Tomosynthesis.
    Manda-Mapalo MT, Fine SG, Safadi S, Lee JH, et al · · 2020 · PMID 32991242 · DOI 10.1089/jwh.2020.8402

Verify or expand the search:

Other recruiting trials for Breast Cancer Screening

Currently open trials in the same condition.

Other New Mexico Cancer Research Alliance trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03979729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing